Hickey to Discuss Medical Marijuana Industry with Sri Lankan Officials
HOUSTON, TX / ACCESSWIRE / January 12, 2015 / Solanbridge Group Inc (OTC: SLNX) is pleased to announce that Earle G. Hickey, President of Solanbridge Group NS, Inc., will be in Sri Lanka this week and plans to meet with the newly elected Executive President of Sri Lanka His Excellency Maithripala Sirisena, concerning the benefits of medical marijuana. This will be Mr. Hickey's fourth trip to Sri Lanka.
Charles R. Shirley, CEO of Solanbridge Group Inc, stated, "We are excited to announce the details of the business trip to Sri Lanka. There has been a great groundswell of support for the legalization of medical marijuana in Sri Lanka and we are happy to provide information, support, and assistance in this area."
The Deputy Minister of Plantation & Industries has written a bill and formed a committee to present to Parliament seeking to change the governing Ayurveda Act, overturning the Sri Lankan ban on marijuana. Some of the key points of the bill reflect the research that verifies its medical efficacy, its fibres can be used to create material for manufacturing products, and Sri Lanka can financially profit from the legalization of the new industry.
Mr. Hickey traveled to Sri Lanka on three occasions and 2014. He began a series of discussions including a meeting with the Minister of Plantations, who is a surgeon by training and also a meeting with the former President of Sri Lanka.
During the previous trips, Mr. Hickey was introduced to Ms. Sumudu Surangi Karunarathna, a small business owner in Kandy engaged in horticulture, landscaping, and plant care. She was instrumental in arranging all meetings with Sri Lankan officials and ensuring administrative, accommodation, and cultural processes operated flawlessly and she currently works within Sri Lanka developing business for Solanbridge. Ms. Karunarathna is a member of the Advisory Board of Solanbridge Group NS Inc.
About Solanbridge Group Inc.
Solanbridge Group Inc, based in The Woodlands, Texas, is a diversified holding company looking to expand into the medical marijuana industry by developing commercial grower's licenses in Eastern Canadian medical marijuana jurisdictions, with the partnership of First Nations and developing CBD-infused products in Colorado and Nevada. Solanbridge is also pursuing other acquisitions in the growing medical marijuana field and partnerships with agribusiness entities in California and Michigan.
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. This presentation contains forward-looking statements that involve substantial risks and uncertainties. You can identify forward-looking statements by words such as anticipate, believe, could, estimate, expect, intend, may, plan, should, will, would or similar words. You should consider these statements carefully because they discuss our plans, targets, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Our actual results may differ materially from the expectations we describe in our forward looking statements. Factors or events that could cause our actual results to materially differ may emerge from time to time, and it is not possible for us to accurately predict all of them. Before you invest in our common stock, you should be aware that the occurrence of any such event could have a material adverse effect on our business, results of operation and financial position. Any forward-looking statement made by us in this presentation speaks only as of the date on which we make it. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Charles R. Shirley
Solanbridge Group Inc
[email protected]
832.225.1372
SOURCE: Solanbridge Group Inc